A higher dose of the flu vaccine provided better protection against respiratory and all-cause hospital admissions.
The ACIP issued new guidelines for the upcoming influenza season including not using live attenuated influenza vaccine because of concerns of effectiveness.
An analysis of the financial burden associated with rotavirus infection revealed a lower cost burden for children receiving complete and incomplete vaccination relative to completely unvaccinated children.
A new longitudinal study updates the epidemiology of acute otitis media in the decade after pneumococcal conjugate vaccine introduction.
Influenza vaccination is recommended annually because of antigenic drift, which warrants the change of influenza vaccine on a year-to-year basis.
From 2009-2010 to 2013-2014, there was a decrease in the prevalence of vaccine-type human papillomavirus among unvaccinated young women, which suggests they are beginning to benefit from herd immunity.
The FDA has updated its list of resolved CBER-regulated product shortages to alert the public that the tetanus and diphteria vaccine shortage has been resolves.
The trivalent, quadrivalent, and recombinant influenza vaccines will be available for use in the 2017-2018 flu season.
Both trivalent and quadrivalent formulations of the influenza vaccine will be offered by Seqirus, which were developed using egg- and cell-based technologies.
Inadvertent administration of the quadrivalent HPV vaccine during periconception or pregnancy was not associated with additional risk to mothers and their infants.
The flu vaccine may have benefits by reducing negative outcomes and mortality associated with contracting influenza.
Human papillomavirus vaccine initiation rates are low among young cancer survivors.
The World Health Organization reports that 12.9 million infants worldwide did not receive any vaccinations in 2016.
One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.
Increasing rates of non-pneumococcal conjugate vaccine 13 serotypes of invasive pneumococcal disease present a new challenge to the global containment of the infection.
The live attenuated influenza vaccine was ineffective among children between 2 and 17 years of age during the 2015-2016 season.
Implementation of rotavirus vaccination correlated with a reduction in acute gastroenteritis related hospitalization rates among children.
The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.
Improving the rates of children and adult influenza vaccination could improve public health drastically.
FDA has granted Fast Track Designation to investigational vaccine for recurrent urinary track infection.
Prior influenza vaccination predicts higher baseline antibody titers and decreased peak antibody responses against all influenza strains in pregnant women.
Influenza vaccination during pregnancy decreases infant hospitalizations for all-cause acute lower respiratory tract infection during the first 3 months of life.
Since the introduction of pneumococcal vaccines, the epidemiology of acute otitis media has changed considerably.
A tetravalent dengue vaccine candidate (TDV) was found to be safe and immunogenic in an ongoing phase 2 trial. A second TDV dose induced enhanced immunogenicity against DENV-3 and DENV-4 in children who were seronegative before vaccination, supporting the initiation of phase 3 trial to evaluate the efficacy and safety of TDV given in a 2-dose schedule 3 months apart.
Sanofi Pasteur announced that the first doses of Fluzone for the upcoming 2017-2018 influenza season have been shipped.
Researchers determined that just a 5% drop in MMR vaccine coverage could triple the number of measles cases ever year.
Sanofi Pasteur announced the total depletion of their stock of yellow fever vaccine YF-VAX.
The FDA has approved the concomitant use of varicella zoster vaccine and inactivated trivalent and quadrivalent influenza vaccines.
A single-dose 13-valent pneumococcal conjugate vaccine (PCV13) was found to be safe and immunogenic for pediatric oncology patients.
GlaxoSmithKline has initiated a voluntary recall of Menveo vaccine for meningitis for intramuscular injection.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- Influenza Vaccine's Effectiveness Following Repeated Vaccination
- FDA Announces Orphan Drug Designation for HDV Drug
- New Single-Assay Test for Vaginitis Accurate as Traditional Tests
- Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat
- Bezlotoxumab Reduces 30-Day Hospital Readmissions for C difficile Infection
- FDA: Vabomere Approved for Complicated UTI Following Priority Review
- HCC Risk After HCV Direct-Acting Antiviral Treatment
- New CDC Guidelines for SSI Prevention Leave Unanswered Questions
- Clinic Visits, Costs Decreased by Rotavirus Vaccination in US Children
- Risk for Secondary Tumors After Kaposi Sarcoma Has Changed in the HAART Era
- FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis
- HIV Risk Behaviors More Prominent in Women With Mental Disorders
- Influenza Vaccine in Elderly Adults: Is High-Dose Better Than Standard-Dose?
- Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children